RBC Comments on Bull/Bear Case on Biogen (BIIB) Following Q3 Results
Tweet Send to a Friend
RBC Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $450. Earlier Biogen reported Q3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
